



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

**Drug Treatment Program**

St. Paul's Hospital  
608-1081 Burrard Street  
Vancouver, BC  
Canada V6Z 1Y6

Tel 604-806-8515  
Fax 604-806-9044  
www.cfenet.ubc.ca

July 12, 2017

**Re: Elvitegravir 150 mg/Cobicistat 150 mg/Emtricitabine (FTC) 200 mg/  
tenofovir alafenamide (TAF) 10 mg (Genvoya®)**

Dear Doctor:

This is to inform you that Genvoya® is available by prescription through the BC Centre for Excellence in HIV/AIDS (BC-CfE) **for patients who require continuation of tenofovir-based therapy and who have documented renal or bone toxicity to tenofovir DF (TDF)**. Genvoya® is not currently available in the absence of documented TDF toxicity.

Under exceptional circumstances Genvoya® requests may be considered for antiretroviral-naïve patients who have renal or bone disease at baseline. These cases will be addressed on a case-by-case basis by the BC-CfE.

The **specific criteria** are (must meet **both** criteria A and B):

- A. Cannot take abacavir, due to HLA-B\*5701 positivity, documented abacavir resistance, or documented significant abacavir intolerance  
**or**  
HBsAg positive (chronic HBV infection)

AND

- B. One or more of the following conditions while receiving TDF:
- eGFR < 60 mL/min for  $\geq 3$  months
  - Severe hypophosphatemia (serum phosphate < 0.32 mmol/L)
  - Documented osteoporosis (at least one T-score  $\leq -2.5$  at the hip or spine on DXA scan)
  - In premenopausal women and men < 50 years of age, a Z score  $\leq -2.0$
  - Fragility fracture (a traumatic fracture or fracture resulting from minimal trauma)
  - Documented osteomalacia (laboratory and/or imaging)

Dosing

Genvoya® is indicated as a complete regimen for treatment of HIV-1 infection. The dose is one tablet taken orally once daily, with food for optimal absorption. Safety of Genvoya® has not been established in patients with estimated creatinine clearance <30mL/min. Genvoya® contains cobicistat, a strong inhibitor of cytochrome P450. Assess for drug-drug interactions when prescribing.

Prescribing


All new prescriptions for Genvoya® require submission of a HIV Drug Treatment Program Prescription Request form. When requesting Genvoya®, **please provide justification** for its use on the prescription form and **appropriate documentation** (i.e. laboratory or DXA scan results). Failure to provide appropriate justification may result in delays in processing your request.

For questions regarding availability of Genvoya®, please contact the St. Paul's Hospital Ambulatory Pharmacy (1-888-511-6222).

Sincerely,



Val Montessori, MD, FRCPC  
Co-Chair, Committee for Drug Evaluation and Therapy  
BC Centre for Excellence in HIV/AIDS



Julio S.G. Montaner MD, FRCPC, FCCP  
Director, BC Centre for Excellence in HIV/AIDS

\kh